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Abstract
Background: Multiple carcinogenesis is one of the major characteristics of human hepatocellular carcinoma (HCC).
The history of multiple tumors, that is, whether they derive from a common precancerous or cancerous ancestor or
individually from hepatocytes, is a major clinical issue. Multiple HCC is clinically classified as either intratumor
metastasis (IM) or multicentric carcinogenesis (MC). Molecular markers that differentiate IM and MC are of interest
to clinical practitioners because the clinical diagnoses of IM and MC often lead to different therapies.
Methods: We analyzed 30 multiple tumors from 15 patients for somatic mutations of cancer-related genes,
chromosomal aberrations, and promoter methylation of tumor suppressor genes using techniques such as high-
resolution melting, array-comparative genomic hybridization (CGH), and quantitative methylation-specific PCR.
Results: Somatic mutations were found in TP53 and CTNNB1 but not in CDKN2A or KRAS. Tumors from the same
patient did not share the same mutations. Array-CGH analysis revealed variations in the number of chromosomal
aberrations, and the detection of common aberrations in tumors from the same patient was found to depend on
the total number of chromosomal aberrations. A promoter methylation analysis of genes revealed dense
methylation in HCC but not in the adjacent non-tumor tissue. The correlation coefficients (r) of methylation
patterns between tumors from the same patient were more similar than those between tumors from different
patients. In total, 47% of tumor samples from the same patients had an r ≥ 0.8, whereas, in contrast, only 18% of
tumor samples from different patients had an r ≥ 0.8 (p = 0.01). All IM cases were highly similar; that is, r ≥ 0.8
(p = 0.025).
Conclusions: The overall scarcity of common somatic mutations and chromosomal aberrations suggests that
biological IM is likely to be rare. Tumors from the same patient had a methylation pattern that was more similar
than those from different patients. As all clinical IM cases exhibited high similarity, the methylation pattern may be
applicable to support the clinical diagnosis of IM and MC.
Background
Human hepatocellular carcinoma (HCC) is one of the
leading causes of death in Asian countries. Unlike can-
cers that are prevalent in other developed countries,
HCC is characterized by underlying viral etiologic fac-
tors, such as hepatitis B virus (HBV) and hepatitis C
virus (HCV). In Japan, HCV infection is the most com-
mon cause of HCC. One characteristic of HCC is a high
rate of tumor recurrence [1-4], owing to multiple carci-
nogenesis. Multiple carcinogenesis is uncommon, except
in HCC and some types of lung cancer. Multiple HCC
is classified as either intrahepatic metastasis (IM) or
multicentric carcinogenesis (MC) based on clinicopatho-
logical criteria [5,6]. Some groups have reported that IM
recurrence develops earlier than MC, which leads to a
poorer prognosis for IM than for MC [2,7]. Therefore,
surgery may not be warranted for recurrent metastatic
nodules, whereas, for MC lesions, radical surgery should
be initially attempted if a functional liver reserve is
adequate.
Numerous studies have investigated the genetic aberra-
tions in HCC [8]. Somatic mutations in genes, such as
TP53, have frequently been observed. Recurring allelic
gains and losses on 14 chromosome arms have been
detected in more than 30% of HCC cases [9-11]. These
observations have been confirmed using array-comparative
* Correspondence: katou-ki@mc.pref.osaka.jp
1Research Institute, Osaka Medical Center for Cancer and Cardiovascular
Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537-8511, Japan
Full list of author information is available at the end of the article
Taniguchi et al. BMC Cancer 2010, 10:530
http://www.biomedcentral.com/1471-2407/10/530
© 2010 Taniguchi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
genomic hybridization (CGH) [12-14]. In addition to these
genetic changes, epigenetic changes have also been exten-
sively analyzed. Dense methylation of cancer-related genes
is a characteristic of HCC [15]. Geographic variations in
methylation status indicate that environmental factors
affect the methylation status of genes in HCC [15]. In
addition, the aberrant hypermethylation has been observed
in non-neoplastic liver cells from patients with hereditary
hemochromatosis [16].
As previously described, a history of multiple tumors
in a single patient has been an important clinical issue.
If there were multiple genomic aberrations, the lineage
of multiple tumors could be deduced from the patterns
of the aberrations. Genetic and epigenetic factors have
been examined for this purpose. These factors include
p53 mutation status [17], HBV integration sites [18],
chromosome aberration [19-22], and methylation status
[23]; however, despite these reports, no consensus lead-
ing to clinical application has been established. This is
not surprising because the biological and genetic bases
of IM and MC remain obscure.
In this study, we analyzed 30 multiple tumors from 15
patients for somatic mutations of cancer-related genes
or chromosomal aberrations (i.e., allelic gains and losses)
and the promoter methylation status of cancer-related
genes using the latest techniques, such as high-resolu-
tion melting [24], array-CGH [25], and quantitative
methylation-specific PCR (QMSP) [26]. We examined
whether multiple HCC has specific molecular changes
that indicate the process of carcinogenesis. We also
evaluated whether these changes could be applicable to
the differentiation of IM and MC.
Methods
HCC samples
A total of 30 tumor tissues and adjacent non-tumor tis-
sues were obtained from 15 HCC patients who under-
went their first surgical operation between 1998 and
2006. Tissues were stored at -80°C until further use.
DNA was extracted from the frozen tumor tissues and
adjacent non-tumor tissues using a QIAamp DNA
Micro kit (Qiagen, Valencia, CA). This study conformed
to the ethical guidelines of the 1975 Declaration of Hel-
sinki and was approved by the ethical committee of
Osaka Medical Center for Cancer and Cardiovascular
Diseases. Informed consent was obtained from all of the
investigated patients.
Mutation analysis
Mutation screening was performed using high-resolution
melting on a LightScanner (Idaho Technology Inc., Salt
Lake City, UT) [24] according to the manufacturer’s
protocol, which was then followed by direct sequencing
of the PCR products. The primer sequences that were
used for both assays are provided in Additional file 1,
Table S1.
Analysis of chromosomal aberration
Array-CGH was performed using a 44K array (Agilent
Technologies, Santa Clara, CA) according to the manu-
facturer’s protocol [25]. Gains and losses that spanned
fewer than 100 probes were omitted from the results in
order to make the output comparable to those from
previous studies that were carried out using conven-
tional CGH or microsatellite markers. The extraction of
data from images was carried out using the Feature
Extraction Software (Agilent Technologies), and gains
and losses were identified using the DNA Analysis Soft-
ware (Agilent Technologies): the ADM-2 algorithm was
employed using 8.0 as the threshold and 0.3219 as the
minimum absolute average log ratio for the region. The
array-CGH data was submitted to NCBI GEO (accession
number, GSE22635).
Methylation analysis
Genomic DNA was subjected to bisulfite treatment
before methylation analysis, as previously described [27].
QMSP was performed as previously described [26] using
TaqMan technology. The primer and probe sequences
that were used are given in Additional file 1, Table S1.
In order to prepare the positive control (i.e., 100%
methylated DNA), we treated a mixture of genomic
DNA from five lung cancer tissues with Sss I (CpG)
methylase (New England Biolabs, Inc., Beverly, MA). In
order to convert the nonmethylated cytosine residues
into uracil, genomic DNA was treated with sodium
bisulfite using the MethylEasy DNA Bisulphite Modifica-
tion kit (TAKARA, Kyoto, Japan). Whereas a 5-methyl
cytosine within the CpG islands remained unaltered, 4
μg of DNA was denatured by NaOH and modified by
sodium bisulfite at 55°C for 12 hr. The DNA samples
were then purified by isopropanol precipitation, washed
with 70% ethanol, and resuspended in 50 μl water. The
samples were then incubated at 72°C for 1 hr.
QMSP for 13 genes was performed using the 7500
Real-Time PCR System(Life Technologies, Carlsbad,
CA). PCR was performed in a total volume of 20 μl,
which consisted of 40 ng bisulfate-modified genomic
DNA, 10 μl TaqMan Universal PCR Master Mix(Life
Technologies, 0.25 μM of each primer, and 0.2 μM of
the TaqMan probe. The primer and probe sequences
that were used here are given in Additional file 1, Table
S1. After an initial denaturation at 50°C for 2 min and
95°C for 5 min, 50 cycles at 95°C for 15 sec and 60°C
for 1 min were performed.
The assays were repeated twice so as to confirm
reproducibility, and the average was used for the subse-
quent data analysis. Data analysis was performed as
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previously described [28]. The values of QMSP that
were obtained from each sample were first normalized
using the value of b-actin as an internal reference. The
values of QMSP that were obtained from the positive
control were also normalized using the value of b-actin.
The percent of methylated reference (PMR) was calcu-
lated as 100 × (normalized value of the sample)/(nor-
malized value of the positive control). For statistical
analysis, the PMR values that were less than 0.01 were
rounded up to 0.01. Subsequently, the PMR values were
converted to logarithms for statistical analysis.
Results
Somatic mutation analysis
The samples from patients 1-9 included pairs of pri-
mary and recurrent tumors, whereas those from
patients 10-15 included multiple primary tumors.
Except for patient no. 11, all HCC patients had back-
grounds of viral infection. All of the clinical informa-
tion is presented in Table 1.
Genes subjected to the somatic mutation analysis -
TP53, CTNNB1 (b-catenin), CDKN2A, and KRAS - were
chosen using COSMIC (Catalog of Somatic Mutation in
Cancer: http://www.sanger.ac.uk/genetics/CGP/cosmic/).
The analysis was conducted using high-resolution melt-
ing and direct sequencing of the PCR products because
direct sequencing often misses mutations on rare alleles;
however, there was no discrepancy of results between
two techniques. In our samples, no mutations were
detected in CDKN2A or KRAS. As shown in Table 1,
somatic mutations in TP53 and CTNNB1 were found to
be associated with several tumors; however, tumors
Table 1 Summary of clinical information and experimental results.
patient HCC_ID Clin. Diag. HBsAg HCV-Ab p53 beta-catenin GMA common aberration r
1 2 MC - + 2.45 + 0.87
4
2 6 MC + - R273H S33C 0 - 0.63
8
3 10 MC - + 2.24 - 0.22
12 Q129stop
4 14 MC - + R249S 8.49 + 0.7
16 S183stop, E298stop
5 18 MC - + S33C 3.16 - 0.8
21
6 102 MC - + Q245C 4.9 - 0.83
104 R249S Q34E
7 106 IM - + 0 - 0.82
108
8 110 IM - + 8.94 + 0.82
112
9 114 MC + - 14.8 + 0.21
116
10 26* MC - + 0 - 0.27
27*
11 29* IM - - Q34E 2 - 0.9
30* V22G, S33S, I35S
12 32* IM + - R175H 0 - 0.87
33*
13 35* MC - + Y163N D32G 10 + 0.63
36* T41I
14 38* MC - + F278A 14.3 + 0.4
39*
15 41* MC + - 1.41 - 0.76
42*
*, tumors dissected at the same operation. Others were sampled at different operations.
GMA, geometric mean of number of chromosomal aberrations; common aberrations, common chromosomal aberrations found in tumors from same patients;
r, correlation coefficient of methylation patterns of tumors from same patients.
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from the same patient did not share the same muta-
tions. Furthermore, no mutations were found in the
non-tumor counterparts (data not shown).
Chromosomal aberration analysis
Chromosomal aberrations (gains and losses) were ana-
lyzed using the 44K human genome array, and the
results are given in Table 2. Chromosome gains and
losses at a probe-level resolution are given in Additional
file 2, Table S2. The overviews of the aberrations were
similar to those that have been published in previous
studies [10,12,14]: frequent gains with 1q (9/30 in Table
2), 8q (12/30), and 20q (5/30) and losses with 1p (5/30),
4q (9/30), 8p (9/30), 13q (6/30), 16q (7/30), and 17p
(10/30). Chromosomal aberrations that are common to
multiple tumors are an important signature for tracing
their histories, in that they indicate that these multiple
tumors share a common lineage. Because array-CGH is
sufficiently refined to determine breakpoints, we
excluded aberrations that had different breakpoints at
both ends from common aberrations. Tumors from six
patients had common aberrations (Table 2, common
aberration). For example, patient no. 13 had common
aberrations in 1p and 17q: tumors no. 35 and 36 were
estimated to have derived from an ancestor that had
these aberrations.
As shown in Table 2, the number of chromosomal
aberrations varied as a function of tumor in different
patients as well as in the same patient. Figure 1 depicts
the geometric mean aberration number in each patient,
grouped according to presence or absence of common
aberrations. There is a marked difference in the numbers
of aberrations between the two groups (Mann-Whitney
test, p < 0.01). Thus, the identification of common aber-
rations depends on the total number of chromosomal
aberrations.
Methylation analysis
The genes that were subjected to the analysis of promo-
ter methylation were mostly tumor suppressor genes,
which are methylation markers that are widely used in
cancer studies. The gene set included all of the genes
that have been used in recent related studies [16,23].
We performed QMSP using all of the tumor samples as
well as adjacent non-tumor samples. The results (PMR)
are given in Additional file 3, Table S3. In most cases,
the amplification using non-tumor samples was less or
far less than the detection level using HCC (Additional
file 3, Table S3), confirming the cancer-specific methyla-
tion of the genes. In HCC, the degree of methylation
differed as a function of the type of gene. Group A
genes tended to have high PMR values, whereas group
B genes tended to have diverse PMR values (Figure 2).
QMSP has a wide dynamic range and is sufficiently sen-
sitive to detect a methylation as low as 0.02%.
Because the methylation status that is described by the
PMR value is not discrete, we compared the overall pat-
terns by calculating the correlation coefficient (r). First,
we calculated the r of log-converted PMRs using all of
the possible combinations of tumors from different
patients. The distribution of r is shown in Figure 3a.
The distribution ranged from 0.96 to -0.14, and the
median was 0.601. This is a control distribution that
was obtained from sample pairs of completely different
origins. The distribution of r of tumors from the same
patient is shown in Figure 3b - this distribution is
shifted to the right, suggesting a greater similarity in
methylation patterns in tumors from the same patient.
In total, 47% (7/15) of cases had an r that was greater
than 0.8 (Figure 3b). In contrast, only 18% of tumors
from different patients had an r that was greater than
0.8 (Figure 3a). The chance of more than seven cases
for which r was more than 0.8 out of 15 sample pairs
from different patients was deduced by randomly sam-
pling 15 cases from the pool of pairs from different
patients: 110 successes per 100,000 trials. The high simi-
larity in methylation patterns in the same patient was,
thus, statistically significant. It should be noted that all
clinical IM cases had values of r that were greater than
0.8 (p = 0.025, Fischer’s exact test) (Table 1). Despite
the detailed examination of the methylation in indivi-
dual genes, we could not find any rule for the high simi-
larity. The high similarity of the overall methylation
patterns is a potential indicator of IM.
Discussion
The origin of individual tumors in HCC is a major issue;
that is, whether they are derived from a common pre-
cancerous or cancerous ancestor or individually from
hepatocytes. We can deduce how individual tumors
evolved from common ancestor cells by comparing the
aberration patterns of multiple genetic aberrations. This
could lead to the differential diagnosis of IM and MC,
which is often important when making a therapeutic
decision. The initial step of the analysis is to find mole-
cular genetic features that are common to individual
tumors. Many efforts have been made to determine
common genetic changes [17-23] and to correlate them
with a clinical diagnosis; however, as described earlier,
there is still no consensus. In this report, we evaluated
somatic mutations, chromosomal aberrations, and pro-
moter methylation. The latest techniques, such as array-
CGH and QMSP, were used for the first time for the
analysis of multiple HCC in this study.
The occurrence of somatic mutations was too rare to
identify common aberrations. Despite the initial effort to
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aberration chrosome gain chrosome loss
1 2 2 2.45 + 6p,8q
4 3 6p, 7q, 8q
2 6 7 0 - 4q,8p,9p,9q,11q,16q,21q
8 0
3 10 5 2.24 - 4p,4q,17p,17q,22q
12 1 9q
4 14 12 8.49 + 1q,11q 3pq,4q,8p,9pq,10q,11p,13pq,16q,17p,Yp
16 6 14q,17q,19q 4q,11pq,13q
5 18 2 3.16 - 8q,Xq
21 5 7p 8p,12p,13q,17p
6 102 1 4.9 - 19p
104 24 1q,5p,5q,6p,8p,8q,11p,11q,20p,20q,Yp,Yq 1p,4p,4q,12p,12q,14q,15q,17p,18p,18q,21q,22q
7 106 0 0 -
108 18 5p,5q,6p,8q,13q,19p,19q,20p,20q,21q,22q,Xp,Xq,Yp 4q,8p,9p,13q
8 110 8 8.94 + 1q,8q,11pq,Yp,Yq 8p,16q,17p
112 10 20q,Yp 1p,6q,8p,16p,16q,18q,Xp,Xq




10 26* 0 0 -
27* 0
11 29* 1 2 - 8q
30* 4 1q,8q,Xq 10q
12 32* 1 0 - 20q
33* 0
13




36* 4 1q,17q 6q,17p
14 38* 12 14.3 + 1q,7pq,19q 1p,4q,5q,7q,8p,16q,17p,18p,18q
39* 17 1q,3q,4p,8q,10q,19q,Xp,Xq 4q,7p,8p,9p,12p,13q,14q,17p,18q
15 41* 1 1.41 - 8q
42* 0
















use p53 for the differential diagnosis [17], we found that
it is mutated in only a few cases, which was similar to
previous reports [29,30]. We found common chromoso-
mal aberrations in six cases, wherein multiple tumors
were likely to have derived from a common lineage;
however, the occurrence of chromosomal aberrations
differed within tumors, as well as among tumors from
the same patient. In cases with infrequent chromosomal
aberrations, it was difficult to deduce the history of
tumors from the aberration pattern. Even tumors with
common aberrations possessed different aberrations and
were not clones. In contrast, we found, from quantita-
tive analysis of CGH patterns, that there was no sub-
stantial heterogeneity in each tumor (data not shown).
These observations suggest that biological IM tumors,
that is, clonal tumors, were rare in comparison to biolo-
gical MC tumors, that is, multiple tumors with different
genotypes, which strongly contrasts with recent observa-
tions in other cancers that have been obtained by large-
scale sequencing. For example, recent work in colorectal
cancer has demonstrated that more than 90% of somatic
mutations were simultaneously present in different
malignant tumors; that is, a primary tumor versus its
metastases or a primary tumor versus a recurrent tumor
in the same patient [31].
As previously described, the choice of therapy often
depends on the clinical diagnosis of IM and MC [5,6].
Multiple HCC is diagnosed as IM when the primary
tumor is moderately or poorly differentiated, and multi-
ple tumors appear within two years after surgery. The
diagnosis of MC is achieved when multiple tumors are
highly differentiated and appear with hepatitis or cirrho-
sis; however, these criteria have no direct correlation
with the process of carcinogenesis. Therefore, an
exploration of the molecular genetic differences between
IM and MC does not have a solid scientific basis. Thus,
it is not surprising that there has been no consensus in
Figure 1 The relationship between the occurrence of
chromosomal aberrations that are common to tumors from
the same patient and the average number of aberrations. Dots
represent cases. (+), Cases with common aberrations; (-), cases
without common aberrations.
Figure 2 The promoter methylation of genes. Vertical axis, PMR values that are converted to common logarithms; horizontal axis, genes that
are subjected to promoter methylation analysis.
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the molecular diagnostic criteria for IM and MC. Our
data concerning somatic mutations and chromosomal
aberrations suggest that biological IM is likely to be
rare. Difficulty in the molecular differentiation of IM
and MC is at least partly due to the rarity of biological
IM.
All IM cases exhibited a similar methylation pattern.
Unlike genetic changes, epigenetic changes were not
necessarily irreversible. Here, a similar methylation pat-
tern for multiple HCC would reflect the environmental
factors that surrounded their development rather than
their derivation from a common ancestor because the
data concerning somatic mutations and chromosomal
aberrations suggest the rarity of biological IM. Although
confirmation with a larger number of patients is still
required, the methylation pattern may be useful in the
clinical diagnosis of marginal cases.
In general, current techniques do not offer adequate
information on the carcinogenesis of multiple HCC.
There is also a possibility that the negative results are
due to the small sample size. Recently, sequencers based
on a new principle have appeared, and the rate of
sequence data production has improved by more than
100 times and is still increasing [32]. The lineage of
multiple tumors and liver tissues and the process of car-
cinogenesis will be identified when the somatic muta-
tions are revealed by the entire genomic sequencing of
multiple HCC.
Conclusions
The overall scarcity of common somatic mutations and
chromosomal aberrations suggest that biological IM is
likely to be rare. Tumors from the same patient had a
methylation pattern that was more similar than tumors
from different patients. Because all clinical IM cases
were highly similar, methylation patterning may be
applicable to support the clinical diagnosis of IM and
MC.
Additional material
Additional file 1: Table S1.
Additional file 2: Table S2.
Additional file 3: Table S3.
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